Digest Network Come funziona
Network
/
Società
Gr
Non verificato

Grünenthal Group

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaOrganizzazione AziendaleSanità

9 comunicati stampa

Guarda tutti i comunicati
02/06/2025
Farmaceutica
Sanità
Economia
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
20/05/2025
Farmaceutica
Sanità
Economia
Management
Organizzazione Aziendale
Maren Thurow starts as new Head Global Communications at Grünenthal
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
24/02/2025
Farmaceutica
Banca
Sanità
Economia
Brevetti, marchi e copyright
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
09/01/2025
Farmaceutica
Sanità
Economia
Management
Organizzazione Aziendale
Biologia
Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
07/11/2024
Farmaceutica
Sanità
Economia
Start-up
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
22/10/2024
Farmaceutica
Sanità
Biologia
First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
30/09/2024
Farmaceutica
Sanità
Economia
Management
Organizzazione Aziendale
Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
22/07/2024
Farmaceutica
Sanità
Economia
Biologia
Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0
17/07/2024
Farmaceutica
Sanità
Economia
Start-up
Biologia
Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients
Fonte
Grünenthal Group
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0